An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients With Chronic Idiopathic Constipation.

Trial Profile

An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients With Chronic Idiopathic Constipation.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational
  • Sponsors Synergy Pharmaceuticals
  • Most Recent Events

    • 19 Jan 2017 According to a Synergy Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved TRULANCE™ (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC).
    • 17 Oct 2016 According to a Synergy Pharmaceuticals media release, new long-term safety data was presented at the American College of Gastroenterology (ACG) annual scientific meeting.
    • 17 Oct 2016 Long term results published in a Synergy Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top